Oxford GlycoSciences Plc and Medarex, Inc. have announced an alliance to develop novel therapeutics produced through the joint application of Medarex’s fully human monoclonal antibody technology and OGS’s proprietary proteomics technology for high-throughput protein analysis and target validation. Antibodies are increasingly being recognized as a rapid and efficient way to move potential products from the Read more about Medarex And Oxford GlycoSciences Form Alliance[…]